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Human RFT1 deficiency leads to a disorder of N-linked
glycosylation
Abstract
N-linked glycosylation is an essential posttranslational modification of proteins in eukaryotes. The
substrate of N-linked glycosylation, dolichol pyrophosphate (DolPP)-GlcNAc(2)Man(9)Glc(3), is
assembled through a complex series of ordered reactions requiring the translocation of the intermediate
DolPP-GlcNAc(2)Man(5) structure across the endoplasmic-reticulum membrane. A young patient
diagnosed with a congenital disorder of glycosylation characterized by an intracellular accumulation of
DolPP-GlcNAc(2)Man(5) was found to carry a homozygous point mutation in the RFT1 gene. The
c.199C-->T mutation introduced the amino acid substitution p.R67C. The human RFT1 protein shares
22% identity with its yeast ortholog, which is involved in the translocation of DolPP-GlcNAc(2)Man(5)
from the cytosolic into the lumenal side of the endoplasmic reticulum. Despite the low sequence
similarity between the yeast and the human RFT1 proteins, we demonstrated both their functional
orthology and the pathologic effect of the human p.R67C mutation by complementation assay in
Deltarft1 yeast cells. The causality of the RFT1 p.R67C mutation was further established by restoration
of normal glycosylation profiles in patient-derived fibroblasts after lentiviral expression of a normal
RFT1 cDNA. The definition of the RFT1 defect establishes the functional conservation of the
DolPP-GlcNAc(2)Man(5) translocation process in eukaryotes. RFT1 deficiency in both yeast and
human cells leads to the accumulation of incomplete DolPP-GlcNAc(2)Man(5) and to a profound
glycosylation disorder in humans.
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Abstract 1 
N-linked glycosylation is an essential post-translational modification of proteins in 2 
eukaryotes. The substrate of N-linked glycosylation, dolichol pyrophosphate 3 
(DolPP)-GlcNAc2Man9Glc3 is assembled through a complex series of ordered 4 
reactions requiring the translocation of the intermediate DolPP-GlcNAc2Man5 5 
structure across the endoplasmic reticulum membrane. A young patient diagnosed 6 
with a congenital disorder of glycosylation, characterized by an intracellular 7 
accumulation of DolPP-GlcNAc2Man5, was found to carry a homozygous point 8 
mutation in the RFT1 gene. The 199C>T mutation introduced the amino acid 9 
substitution R67C. The human RFT1 protein shares 22% identity with its yeast 10 
homolog, that is involved in the translocation of DolPP-GlcNAc2Man5 from the 11 
cytosolic into the lumenal side of the endoplasmic reticulum. Despite the low 12 
sequence similarity between the yeast and human RFT1 proteins, we demonstrated 13 
both their functional orthology, and the pathologic effect of the human R67C 14 
mutation by complementation assay in Δrft1 yeast cells. The causality of the RFT1 15 
R67C mutation was further established by restoring normal glycosylation profiles in 16 
patient derived fibroblasts after lentiviral expression of a normal RFT1 cDNA. The 17 
definition of the RFT1 defect establishes the functional conservation of the DolPP-18 
GlcNAc2Man5 translocation process in eukaryotes. RFT1 deficiency in both yeast and 19 
human cells leads to the accumulation of incomplete DolPP-GlcNAc2Man5 and to a 20 
profound glycosylation disorder in humans. 21 
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Introduction 1 
N-linked glycosylation is an ubiquitous posttranslational modification of proteins in 2 
eukaryotes. N-glycans convey essential signals for the folding and intracellular 3 
trafficking of glycoproteins (Helenius and Aebi 2004). N-glycans also influence the 4 
clearance of circulating glycoproteins (Mi et al. 2002) and the stability of signaling 5 
proteins at the cell surface (Chantret et al. 2003). A particular feature of N-glycans is 6 
that they are first assembled in the endoplasmic reticulum (ER) as lipid-linked 7 
oligosaccharides (LLO). This assembly proceeds through the sequential addition of 8 
monosaccharides to the growing LLO.  The process begins by the addition of GlcNAc 9 
monophosphate to dolichol phosphate (DolP) and ends with the formation of DolPP-10 
GlcNAc2Man9Glc3. The oligosaccharide is transferred to selected asparagine residues 11 
of nascent glycoproteins (Burda and Aebi 1999). The assembly of LLO requires 12 
glycosyltransferases and their respective nucleotide- and dolichol-activated 13 
monosaccharide substrates, but also several proteins that regulate the complex 14 
topology of the process. For example, the MPDU1 protein makes the donor 15 
substrates DolP-Man and DolP-Glc available for the completion of the LLO beyond 16 
DolPP-GlcNAc2Man5 (Anand et al. 2001; Kranz et al. 2001; Schenk et al. 2001). 17 
Similarly, it was previously shown that in yeast the Rft1 protein is essential for the 18 
translocation of the cytosolically oriented intermediate DolPP-GlcNAc2Man5 into the 19 
ER lumen, where LLO assembly is completed (Helenius et al. 2002). 20 
The pathway of LLO assembly is strongly conserved among eukaryotes. 21 
Homologous genes can be found from yeasts to humans for all glycosyltransferases 22 
involved. However, it is unclear whether the same degree of conservation applies to 23 
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the accessory proteins. In fact, whereas MPDU1 homologs can be found in metazoan 1 
and plant genomes, no orthologous gene can be identified in the yeast genome. In the 2 
case of RFT1, only genes with limited sequence similarity can be retrieved from the 3 
genome of higher organisms, thus casting doubt upon the functional significance of 4 
RFT1 in the assembly of LLO in general. 5 
The identification of N-linked glycosylation disorders in humans, often referred to as 6 
congenital disorders of glycosylation (CDG), has demonstrated the conservation of 7 
the LLO assembly pathway between yeasts and humans (Aebi and Hennet 2001). The 8 
expression of human glycosyltransferase genes in yeasts exhibiting the same 9 
glycosylation defects demonstrated both the functional orthology of the 10 
glycosyltransferases studied and the pathological effect of the mutations identified in 11 
CDG cases (Imbach et al. 1999; Grubenmann et al. 2002; Frank et al. 2004; 12 
Grubenmann et al. 2004). 13 
In spite of the extensive use of the yeast as a road map, many cases of CDG have 14 
remained untyped. Clinically, these cases present the symptoms typically seen in 15 
CDG patients, i.e. neurological abnormalities, failure to thrive and varying degrees of 16 
dysmorphism (Schenk et al. 2001; Wu et al. 2003). In the present study, we have 17 
identified a novel glycosylation defect in such an untyped CDG case, which 18 
establishes the importance of the RFT1 protein in human N-linked glycosylation. 19 
20 
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Materials and methods 1 
LLO and NLO analysis - The investigation of the patient material was approved by 2 
the Ethical Commission of the Kanton Zürich. Fibroblasts were grown in DMEM 3 
(Gibco) containing 25 mM Glc and 10% FCS until 90% of confluence. At this point, 4 
the fibroblasts were rinsed in PBS and incubated in Glc-/FCS-free DMEM for 45 min, 5 
then labeled by adding 150 μCi of [3H]-Man (54.0 Ci/mmol, Amersham Bioscience) 6 
for 60 min. LLO and N-linked oligosaccharides (NLO) were isolated from labeled 7 
fibroblasts by chloroform/methanol/ water extraction as described previously 8 
(Grubenmann et al. 2004). Oligosaccharides were released from LLO by mild acid 9 
hydrolysis and from NLO by N-glycosidase F (New England BioLabs) digestion 10 
(Grubenmann et al. 2004) and subjected to HPLC (Zufferey et al. 1995). 11 
Mutation analysis –Total RNA and genomic DNA were isolated from 2 x 107 12 
fibroblasts and 5 ml blood samples, respectively, using the TRIzol LS reagent 13 
(Invitrogen) according to the manufacturer’s instructions. The human RFT1 cDNA 14 
was prepared from 2 μg of total RNA using the primer 5’-15 
GGGCTTTTGGTCTTCACT-3’ and 2 units of Omniscript reverse transcriptase 16 
(Qiagen). The 20 μl reaction mixtures were incubated at 37 °C for 1 h. The protein-17 
coding region of the human RFT1 cDNA was amplified by PCR from 2 μl of RT 18 
product with the primers 5’-GGCGGCATTTCCTGGTGTCT-3’ and 5’-19 
TGGCACTCTCTGGTGCCTCATC-3’. The exon 3 of the human RFT1 gene was 20 
amplified by PCR from 50 ng of genomic DNA with the primers 5’-21 
GGGCAATTCAGCTTTAGG-3’ and 5’-CACCACCAGTGGTTTATG-3’. The PCR 22 
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products were sequenced (Synergene Biotech, Switzerland) after removal of the 1 
unincorporated nucleotides with QIAquick columns (Qiagen).  2 
Plasmid construction - For construction of the lentiviral expression vector, the 3 
human RFT1 cDNA was subcloned as a PCR fragment flanked by SpeI and XhoI 4 
restriction sites into the NheI and SalI sites of the pLenti6-EGFP plasmid (Invitrogen), 5 
thus yielding the pLenti6-hRFT1 vector. The yeast rft1 gene with promoter and 6 
terminator sequences was amplified from S.cerevisiae genomic DNA by PCR and 7 
ligated into YCplac33 (Gietz and Sugino 1988; Kastaniotis et al. 2004) using the 8 
inserted 5’-PstI and 3’-BamHI restriction sites to generate YCplac33-ScRFT1. The 9 
pTSV30A-ScRFT1 (Gietz and Sugino 1988; Kastaniotis et al. 2004) plasmid was 10 
obtained by subcloning ScRFT1 from YCplac33-ScRFT1 using SacI and BamHI 11 
restriction sites. Plasmid YCplac33-pGAL1 was constructed by amplification of the 12 
GAL1 promoter from pYES2 (Invitrogen) and ligation of the PCR product into 13 
YCplac33 using the inserted restriction sites 5’-HindIII and 3’-XbaI. The human RFT1 14 
cDNA was obtained via the EST clone IMAGE: 6422683 (Geneservice, UK). For 15 
construction of the plasmid YCplac33 pGAL1-hRFT1, the human RFT1 ORF was 16 
amplified from the IMAGE clone by PCR and cloned into plasmid YCplac33 pGAL1 17 
using the inserted restriction sites 5’-XbaI and 3’-SacI. The mutant RFT1[R67C] cDNA 18 
from the CDG patient was subcloned into YCplac33 pGAL1 hRFT1, resulting in 19 
YCplac33-pGAL1-hRFT1[R67C].  20 
Complementation of rft1Δ yeast mutants - Yeast strains W1536 5B (MATa, ade2Δ, 21 
ade3Δ, can1-100, his3-11,15, leu2-3,112, trp1-1, ura3-1) and W1536 8B (isogenic MATα 22 
strain) have been described earlier (Kastaniotis et al. 2004). The diploid W1536a/α 23 
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was obtained by mating W1536 5B and W1536 8B. W1536 5B-rft1Δ was generated by 1 
introducing the rft1::KanMX4 gene replacement cassette into W1536a/α and selecting 2 
for geneticin resistance, followed by tetrad dissection on a Singer MSM manual 3 
dissection microscope (Singer Instrument). Haploid W1536 5B-rft1Δ mutant cells 4 
carry plasmid-borne rft1 to be viable. The yeast cells were grown on either rich YPD 5 
(1% yeast extract, 2% peptone and 2% D-glucose), YPGalD (1% yeast extract, 2% 6 
peptone, 2% D-galactose and 0.05% D-glucose), YPR (1% yeast extract, 2% peptone 7 
and 2% D-raffinose) or synthetic complete media (Sigma or QBiogene) lacking one or 8 
more nutrients. The colony-sectoring method has been described by Bender et al. 9 
(Bender and Pringle 1991). CPY western blotting was performed as described 10 
elsewhere (Burda et al. 1996). 11 
Lentiviral mediated RFT1 expression - HEK293T cells (3 x 106) were transfected with 12 
20 μg of pLenti6-hRFT1 and 36 μg of the packing plasmid mix (Invitrogen) using 13 
calcium-phosphate precipitation. Eight hour post transfection, the medium was 14 
replaced with fresh DMEM containing 10% FCS. The cell supernatant was collected 15 
after 48 h and lentiviruses were harvested by centrifugation at 3000 x g for 5 min and 16 
filtration through 0.45 μm membranes (Schleicher & Schuell, Germany). CDG and 17 
healthy control fibroblasts were infected with recombinant lentiviral particles 18 
including the human RFT1 cDNA or the EGFP gene as control. Infected cells were 19 
selected with 5 μg/ml blasticidin (Invitrogen) for 10 days. 20 
21 
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Results 1 
A young girl was diagnosed with a disorder of N-linked glycosylation based on the 2 
detection of abnormal isoelectric focusing of serum transferrin (Stibler et al. 1998). 3 
The patient showed symptoms often encountered in CDG, namely a marked 4 
developmental delay, hypotonia, seizures, hepatomegaly and coagulopathy (Imtiaz 5 
et al. 2000). Phosphomannomutase and phosphomannose isomerase deficiencies 6 
were ruled out by enzymatic testing (data not shown). To determine whether the 7 
glycosylation disorder was related to a defect of LLO assembly, we analyzed the LLO 8 
composition in healthy control and the patient fibroblasts. The LLO profile of control 9 
fibroblasts was dominated by the full-length DolPP-GlcNAc2Man9Glc3 (Fig. 1A). By 10 
contrast, the profile of the CDG patient was marked by an accumulation of the 11 
intermediate LLO DolPP-GlcNAc2Man5 whereas the complete LLO DolPP-12 
GlcNAc2Man9Glc3 was strongly reduced (Fig. 1B). The analyses of NLO produced 13 
after 1 h labeling of healthy control and CDG fibroblasts with [3H]Man were 14 
indistinguishable. Both profiles showed peaks corresponding to GlcNAc2Man8 and 15 
GlcNAc2Man9 oligosaccharides (Fig. 1C, D), which are normally found on 16 
glycoproteins after trimming of the N-linked glycans by the ER glucosidases-I, –II 17 
and ER mannosidase. The absence of GlcNAc2Man5 in the NLO profile of the CDG 18 
patient suggested that only the full-length DolPP-GlcNAc2Man9Glc3 was transferred 19 
to glycoproteins.  This phenotype was reminiscent of the LLO/NLO profiles 20 
described in yeast depleted for the Rft1 protein (Helenius et al. 2002). In conditions 21 
with limiting RFT1  activity, DolPP-GlcNAc2Man5 accumulates at the cytosolic side 22 
of the ER membrane, whereas the small amounts of flipped oligosaccharide are 23 
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extended to DolPP-GlcNAc2Man9Glc3 and transferred to proteins. This results in the 1 
underglycosylation of N-glycoproteins.  2 
The search for a human homolog to the yeast Rft1 protein pointed to a single gene, 3 
GeneBank# BC043595, which encoded a protein of 541 amino acids sharing 22% 4 
identity with yeast Rft1. Sequencing of the BC043595 cDNA in the CDG fibroblasts 5 
revealed a C to T transition at nucleotide position 199 (Fig. 2A). This point mutation 6 
led to the amino acid substitution R67C in the human RFT1 protein homolog. The 7 
analysis of the BC043595 gene in the DNA of the CDG patient’s parents confirmed 8 
the heterozygosity (Fig. 2B). The R67C mutation was localized to a 50 amino acid-9 
long hydrophilic stretch in the overall hydrophobic Rft1 protein homolog (Fig. 2C). 10 
Genes encoding proteins with varying degrees of similarity to the human RFT1 11 
protein can be retrieved from all eukaryote genomes analyzed, for which the 12 
sequence identity ranges from 87% for the mouse homolog down to 17% for fungal 13 
homologs (Fig. 3). Although the overall identity is limited, some regions of RFT1 are 14 
strongly conserved across species. It is noteworthy that the region comprising the 15 
R67C mutation was strongly conserved and several arginine residues, including R67 16 
in the human protein, were found in all sequences analyzed (Fig. 3), suggesting the 17 
importance of these amino acids for proper functionality. 18 
Growth of the yeast strain W1536-5B-rft1Δ relies on the presence of the yeast rft1 19 
locus on the plasmid pTSV30A-ScRFT1. Cells carrying this plasmid develop a red 20 
pigment, due to the presence of the ade3 locus, whereas loss of the plasmid results in 21 
white cells (Bender and Pringle 1991). Accordingly, this strain forms colonies that are 22 
uniformly red. However, this strain was transformed with the additional plasmid 23 
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YCplac33pGAL1-hRFT1 that leads to the expression of the human RFT1 cDNA 1 
controlled by the galactose-inducible GAL1 promoter. Such cells form colonies that 2 
contain white sectors due to the fact that the pTSV30A-ScRFT1 plasmid was no 3 
longer essential for growth and the plasmid could be lost, as visualized by the white 4 
sectors. This indicated functional complementation of the rft1 defect by expression of 5 
the human RFT1 cDNA (Fig. 4A). This experiment demonstrated that the human 6 
cDNA investigated does indeed encode the orthologous protein to yeast Rft1. The 7 
same experiment performed with a plasmid expressing the CDG RFT1[R67C] allele 8 
did not yield any sectoring colonies (Fig. 4A), thus demonstrating that the R67C 9 
mutation led to reduced function even in the yeast system. As shown previously 10 
(Helenius et al. 2002), Rft1 depletion in yeast leads to the underglycosylation of the 11 
vacuolar N-linked glycoprotein carboxypeptidase Y. When W1536 5B-rft1Δ yeasts 12 
were complemented with YCplac33 pGAL1-hRFT1, a normal carboxypeptidase Y 13 
glycosylation profile was restored (Fig. 4B), thus showing that the effect of the 14 
human RFT1 on rft1Δ yeast was indeed related to N-glycosylation. 15 
Finally, we introduced a normal human RFT1 cDNA in the fibroblasts of the CDG 16 
patient to demonstrate that the glycosylation disorder was the consequence solely of 17 
the RFT1 mutation identified. Healthy control and CDG fibroblasts were infected 18 
with recombinant lentiviruses expressing either the normal RFT1 cDNA or EGFP as a 19 
negative control. The analysis of LLO profiles in the infected fibroblasts showed an 20 
increased formation of the full-length DolPP-GlcNAc2Man9Glc3 and a reduced 21 
presence of DolPP-GlcNAc2Man9 (Fig. 5A), whereas the EGFP expression control had 22 
no influence on the LLO profile (Fig. 5B). The expression of either normal human 23 
  11 
RFT1 or EGFP in healthy control fibroblasts had no effect on the LLO profiles (data 1 
not shown).  2 
3 
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Discussion 1 
The identification of a human glycosylation disorder associated with an RFT1 defect 2 
underlines the functional conservation of the RFT1 protein in eukaryotes. In spite of a 3 
limited sequence similarity between the yeast and the human RFT1 proteins, RFT1 4 
deficiency led to identical phenotypes in both species, i.e. to an accumulation of the 5 
LLO DolPP-GlcNAc2Man5, underglycosylation and thus to a severe disease in 6 
humans. Clinically, the RFT1-deficient CDG patient presented with symptoms 7 
frequently encountered in CDG patients, namely failure to thrive, psychomotor 8 
retardation, seizures, hypotonia and coagulopathy. Among the various types of 9 
CDG, the clinical severity of the RFT1 deficiency resembled the disease caused by 10 
ALG3 and DPM1 deficiencies, also known as CDG-Id (Korner et al. 1999) and CDG-11 
Ie (Imbach et al. 2000; Kim et al. 2000), respectively. The ALG3 gene encodes the 12 
DolP-Man dependent mannosyltransferase that catalyzes the elongation of LLO from 13 
DolPP-GlcNAc2Man5 to DolPP-GlcNAc2Man6 (Aebi et al. 1996). The DPM1 protein is 14 
the catalytic subunit of the DolP-Man synthase complex (Maeda et al. 2000). In CDG-15 
Ie, the shortage in DolP-Man impairs the elongation of the LLO DolPP-GlcNAc2Man5 16 
in the ER lumen. Although DPM1, ALG3 and RFT1 defects all lead to the 17 
accumulation of DolPP-GlcNAc2Man5, their impact on protein N-glycosylation is 18 
expected to be different. In fact, RFT1 defect yields complete LLO structures for the 19 
transfer to proteins, yet in limited amount, whereas ALG3 and DPM1 defects yield 20 
low amounts of complete LLO combined with the lumenal accumulation of the 21 
DolPP-GlcNAc2Man5. The clinical similarity between these three glycosylation 22 
defects suggests that the limited availability of complete LLO alone dictates the 23 
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extent of the clinical manifestations. In any case, the characterization of additional 1 
cases of RFT1 deficiency will allow refining the degree of severity associated with 2 
this type of glycosylation disorder. 3 
The functional conservation of the yeast and human RFT1 proteins emphasizes the 4 
essential role of RFT1 in lower and higher eukaryotes. However, the function of the 5 
RFT1 protein still remains unclear. The contribution of RFT1 to the specific 6 
translocation of DolPP-GlcNAc2Man5 suggests that it may function as a flippase 7 
(Helenius et al. 2002), although such an activity could not be confirmed in vitro. A 8 
similar uncertainty relates to the function of the MPDU1 protein (Anand et al. 2001), 9 
which is involved in making DolP-Man and DolP-Glc substrates available to ER 10 
lumenal mannosyl- and glucosyltransferases. It is presently unclear whether MPDU1 11 
affects the flipping of these substrates across the ER membrane or whether MPDU1 12 
affects their local concentration by a different mechanism. It is noteworthy that a 13 
deficiency of MPDU1 in humans leads to CDG, which is associated with the parallel 14 
accumulation of the LLO DolPP-GlcNAc2Man5 and DolPP-GlcNAc2Man9 (Kranz et 15 
al. 2001; Schenk et al. 2001). 16 
To date, 20 forms of CDG have been divided into 12 types of CDG-I and 8 types of 17 
CDG-II based on the nature of the glycosylation defects (Aebi et al. 1999). This 18 
division becomes obsolete as defects of vesicular transport and of LLO translocation 19 
become associated with glycosylation disorders. Therefore, we suggest to refer to the 20 
present glycosylation disorder as CDG-RFT1, for CDG caused by RFT1 deficiency. 21 
Alternatively, RFT1 deficiency could be referred to as CDG-In according to the 22 
guidelines previously established (Aebi et al. 1999).     23 
24 
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Figure legends 1 
Figure 1. Lipid-linked and N-linked oligosaccharide profiles. The LLO isolated 2 
from healthy (A) and CDG (B) fibroblasts were separated by HPLC, demonstrating 3 
the abnormal accumulation of DolPP-GlcNAc2Man5 in the CDG sample. The NLO 4 
isolated from healthy (C) and CDG (D) fibroblasts were identical, showing that 5 
complete oligosaccharides were transferred to nascent proteins in the CDG cells. The 6 
retention times of DolPP-GlcNAc2Man1 (M1) to DolPP-GlcNAc2Man9Glc3 (M9G3) 7 
derived from a yeast standard LLO are marked at the top of the profiles.  8 
 9 
Figure 2. Mutation analysis of human RFT1 in CDG. Electropherograms of RFT1 10 
cDNA surrounding nucleotide position 199, marked by an arrow, sequenced from 11 
normal control and patient cDNA (A). The same region was sequenced from the 12 
genomic DNA of the CDG patient’s parents (B), showing the heterozygozity for the 13 
C199T mutation. (C) The resulting R67C substitution, marked with a star, was 14 
predicted to be localized in a hydrophilic loop within the highly hydrophobic RFT1 15 
protein. A potential N-glycosylation site detected at position N227 is shown 16 
schematically. 17 
 18 
Figure 3. RFT1 protein sequence comparison. Amino acid sequences of proteins 19 
derived from Homo sapiens, Mus musculus, Danio rerio, and Caenorhabditis elegans 20 
showing similarity to the Saccharomyces cerevisiae RF1 protein as performed by 21 
ClustalW analysis (Thompson et al. 1994). Residues conserved in all five species are 22 
shown in black. The R residue at position 67 in the human RFT1 protein (see arrow) 23 
  21 
is conserved in the five species. Total amino acid identity with the human sequence 1 
ranged from 87% for the mouse protein down to 22% for the S. cerevisiae Rft1 protein.  2 
 3 
Figure 4. Complementation of rft1Δ yeasts.  W1536 5B rft1Δ/ pTSV30A-ScRFT1 cells 4 
transformed with a plasmid carrying a complementing RFT1 variant will form 5 
sectored colonies as they are allowed to lose the red pigment –inducing pTSV30A -6 
ScRFT1 plasmid.  Cells were transformed with: YCplac33 (mock), YCp33 GAL 7 
ScRFT1, YCp33 GAL hRFT1[R67C] and YCp33 GAL hRFT1 (A). Western blotting 8 
analysis of the yeast strain W1536 rftΔ transformed with yeast and human RFT1 9 
expressed from the yeast GAL1 promoter showed a near wild type levels of 10 
carboxypeptidase Y glycosylation when grown on 2 % Gal [G], and an accumulation 11 
of underglycosylated isoforms when  RFT1 expression was repressed by 4% Glc [D] 12 
(B). Carbon source did not affect carboxypeptidase Y glycosylation in wild type yeast 13 
(left panel).  14 
 15 
Figure 5. Lentiviral mediated complementation in CDG fibroblasts. The LLO 16 
profiles of fibroblasts infected with recombinant lentiviruses expressing either 17 
human RFT1 (A) or EGFP as negative control (B) were analyzed. The profiles show 18 
that the expression of the normal RFT1 cDNA in CDG fibroblasts restored the 19 
synthesis of DolPP-GlcNAc2Man9Glc3. The expression of EGFP in CDG fibroblasts 20 
had no effect on the pathologic profile characterized by the accumulation of DolPP-21 
GlcNAc2Man5. The retention times of DolPP-GlcNAc2Man1 (M1) to DolPP-22 
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